Skip to main content

MoneyWorks4Me

Everest Organics - Quaterly Results

13 Nov 2026 Evaluate
Net sales declined -5.14%  to  Rs. 483.79 million from Rs. 510.02 millions.A big decline of -30.74% was reported for the quarter ended September 2026 to Rs. 8.00  millions from Rs. 11.55 millions of corresponding previous quarter.Operating profit for the quarter ended September 2026 decreased to 44.63 millions as compared to 54.20 millions of corresponding quarter ended September 2025.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202609 202509 % Var 202609 202509 % Var 202603 202503 % Var
Sales 483.79 510.02 -5.14 968.10 1048.15 -7.64 1961.58 1594.79 23.00
Other Income 0.20 2.89 -93.08 4.39 8.39 -47.68 12.47 6.87 81.51
PBIDT 44.63 54.20 -17.66 92.09 104.06 -11.50 210.57 79.10 166.21
Interest 16.52 12.31 34.20 32.81 25.38 29.28 65.28 51.90 25.78
PBDT 28.11 41.89 -32.90 59.28 78.68 -24.66 145.29 27.20 434.15
Depreciation 15.89 15.16 4.82 31.78 30.31 4.85 64.83 59.62 8.74
PBT 12.22 26.73 -54.28 27.50 48.37 -43.15 80.46 -32.42 -348.18
TAX 4.22 15.18 -72.20 8.37 22.77 -63.24 25.00 -19.52 -228.07
Deferred Tax -1.88 6.11 -130.77 -5.03 10.09 -149.85 2.40 -19.52 -112.30
PAT 8.00 11.55 -30.74 19.13 25.60 -25.27 55.46 -12.90 -529.92
Equity 99.74 97.10 2.72 99.74 97.10 2.72 97.10 97.10 0.00
PBIDTM(%) 9.23 10.63 -13.19 9.51 9.93 -4.19 10.73 4.96 116.43
Peers
Company Name CMP
Sun Pharma. Inds. 1894.90
Dr. Reddys Labs. 1391.10
Cipla 1409.75
Lupin 1985.85
Zydus Lifesciences 1192.00
View more..